skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

もっと見る

Resources

もっと見る

もっと見る

Products

もっと見る

もっと見る

89 Total results for product and free and sample content found

Citeline

COVID-19 Vaccination Programs And Implications Of The Human Microbiome

COVID-19 Vaccination Programs And Implications Of The Human Microbiome

It is vital to understand the role of the microbiome in immunity and vaccine response, and how the microbiome may impact the effectiveness of COVID-19 vaccine programs in the real world.

Topic Coronavirus

ターゲット市場の実像をつかむ, 世界の薬事規制動向&情報を配信

Oncology Accelerated Approval Withdrawals: Which Indications Need Confirmation Next?

Oncology Accelerated Approval Withdrawals: Which Indications Need Confirmation Next?

The FDA Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals has already led to withdrawals of four PD-1/PD-L1 inhibitor indications, with the Oncologic Drugs Advisory Committee set to review another six in late April. Over the next two years, an additional five indications may be up for review.

Topic Drug Approval Standards fda

Trialtrove: 医療用医薬品の臨床試験情報データベース

The Lost Trials of 2020

The Lost Trials of 2020

Disruption to clinical trials was a well-documented side effect of the COVID-19 pandemic, with trial sponsors and clinical sites dramatically scaling back activities in line with increased hospital burden, lockdown measures, and reduced patient mobility. 

Topic Coronavirus clinical-trials clinical-trials-blog biopharmaceutical

ターゲット市場の実像をつかむ

Pharma Must Not Let Its COVID-19 Halo Slip

Pharma Must Not Let Its COVID-19 Halo Slip

Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination.

Topic Coronavirus immuno-oncology biopharmaceutical

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Pharma360: Improving the Speed to Insight

Finding and organizing critical pharmaceutical and medtech data has long been a tedious task requiring hours spent gathering information from disparate sources. Pharma360 aims to change that.  

Topic Market Intelligence Outlook medtech Combination Products Launches Platform Technologies drug-development-landscape

Pharmaprojects: 医薬品開発パイプラインのデータベース

To infinity and beyond: how far can mRNA vaccine technology go?

 To infinity and beyond: how far can mRNA vaccine technology go?

With over 63 million confirmed cases and over 1.4 million deaths worldwide as of the start of December, the COVID-19 pandemic has certainly lit a fire under the pharmaceutical industry in the pursuit of therapeutics. In the process, with the recent emergency use authorisation in the UK for Pfizer and BioNTech’s BNT-162b2 vaccine, and the 94.5% efficacy reported by Moderna for its mRNA-1273 vaccine, a new technology has shot to the forefront: the mRNA vaccine.

Topic Diseases Drug Development Landscape Vaccines

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

mHealth and Research in Oncology

mHealth and Research in Oncology

The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit. 

Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biom...

Gene therapy manufacturers

Gene therapy manufacturers

Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.

Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor...

Deconstructing the KRAS+ market opportunity

Deconstructing the KRAS+ market opportunity

With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target

Topic biopharmaceutical drug-review

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問い合わせの際は下記のフォームまたはメールアドレスをご利用下さい。

Eメール:inquiry.jp@informa.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。